MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene

G. Ke, L. Liang, J. M. Yang, X. Huang, D. Han, S. Huang, Y. Zhao, R. Zha, X. He, X. Wu

Research output: Contribution to journalArticle

72 Citations (Scopus)

Abstract

The purpose of this study was to define the roles of miR-181a in determining sensitivity of cervical cancer to radiation therapy, to explore the underlying mechanism and to evaluate the potential of miR-181a as a biomarker for predicting radio-sensitivity. Tumor specimens from 18 patients with a histological diagnosis of squamous cervical carcinoma (stage IIIB) were used in the micro-RNA profiling and comparison. These patients never received any chemotherapy before radiation therapy. Human cervical cancer cell lines, SiHa and Me180, were used in vitro (cell culture) and in vivo (animal) studies. Transfection of tumor cells with the mimic or inhibitor of miR-181a, and reporter gene assay, were performed to investigate the role of miR-181a in determining radio-sensitivity and the target gene. Higher expression of miR-181a was observed in human cervical cancer specimens and cell lines that were insensitive to radiation therapy, as compared with sensitive cancer specimens and the cell lines. We also found that miR-181a negatively regulated the expression of PRKCD, a pro-apoptotic protein kinase, via targeting its 3′-untranslated region (UTR), thereby inhibiting irradiation-induced apoptosis and decreasing G 2/M block. The role of miR-181a in conferring cellular resistance to radiation treatment was validated both in cell culture models and in mouse tumor xenograft models. The effect of miR-181a on radio-resistance was mediated through targeting the 3′-UTR of PRKCD gene. Thus, the expression level of miR-181a in cervical cancer may serve as a biomarker for sensitivity to radiation therapy, and targeting miR-181a may represent a new approach to sensitizing cervical cancer to radiation treatment.

Original languageEnglish (US)
Pages (from-to)3019-3027
Number of pages9
JournalOncogene
Volume32
Issue number25
DOIs
StatePublished - Jun 20 2013

Fingerprint

Uterine Cervical Neoplasms
Radiotherapy
Radio
Genes
3' Untranslated Regions
Cell Line
Neoplasms
Cell Culture Techniques
Biomarkers
Radiation
Apoptosis Regulatory Proteins
MicroRNAs
Reporter Genes
Heterografts
Protein Kinases
Transfection
Squamous Cell Carcinoma
Apoptosis
Drug Therapy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Ke, G. ; Liang, L. ; Yang, J. M. ; Huang, X. ; Han, D. ; Huang, S. ; Zhao, Y. ; Zha, R. ; He, X. ; Wu, X. / MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. In: Oncogene. 2013 ; Vol. 32, No. 25. pp. 3019-3027.
@article{747e66288e1c444297d67eba0537605b,
title = "MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene",
abstract = "The purpose of this study was to define the roles of miR-181a in determining sensitivity of cervical cancer to radiation therapy, to explore the underlying mechanism and to evaluate the potential of miR-181a as a biomarker for predicting radio-sensitivity. Tumor specimens from 18 patients with a histological diagnosis of squamous cervical carcinoma (stage IIIB) were used in the micro-RNA profiling and comparison. These patients never received any chemotherapy before radiation therapy. Human cervical cancer cell lines, SiHa and Me180, were used in vitro (cell culture) and in vivo (animal) studies. Transfection of tumor cells with the mimic or inhibitor of miR-181a, and reporter gene assay, were performed to investigate the role of miR-181a in determining radio-sensitivity and the target gene. Higher expression of miR-181a was observed in human cervical cancer specimens and cell lines that were insensitive to radiation therapy, as compared with sensitive cancer specimens and the cell lines. We also found that miR-181a negatively regulated the expression of PRKCD, a pro-apoptotic protein kinase, via targeting its 3′-untranslated region (UTR), thereby inhibiting irradiation-induced apoptosis and decreasing G 2/M block. The role of miR-181a in conferring cellular resistance to radiation treatment was validated both in cell culture models and in mouse tumor xenograft models. The effect of miR-181a on radio-resistance was mediated through targeting the 3′-UTR of PRKCD gene. Thus, the expression level of miR-181a in cervical cancer may serve as a biomarker for sensitivity to radiation therapy, and targeting miR-181a may represent a new approach to sensitizing cervical cancer to radiation treatment.",
author = "G. Ke and L. Liang and Yang, {J. M.} and X. Huang and D. Han and S. Huang and Y. Zhao and R. Zha and X. He and X. Wu",
year = "2013",
month = "6",
day = "20",
doi = "10.1038/onc.2012.323",
language = "English (US)",
volume = "32",
pages = "3019--3027",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "25",

}

Ke, G, Liang, L, Yang, JM, Huang, X, Han, D, Huang, S, Zhao, Y, Zha, R, He, X & Wu, X 2013, 'MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene', Oncogene, vol. 32, no. 25, pp. 3019-3027. https://doi.org/10.1038/onc.2012.323

MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene. / Ke, G.; Liang, L.; Yang, J. M.; Huang, X.; Han, D.; Huang, S.; Zhao, Y.; Zha, R.; He, X.; Wu, X.

In: Oncogene, Vol. 32, No. 25, 20.06.2013, p. 3019-3027.

Research output: Contribution to journalArticle

TY - JOUR

T1 - MiR-181a confers resistance of cervical cancer to radiation therapy through targeting the pro-apoptotic PRKCD gene

AU - Ke, G.

AU - Liang, L.

AU - Yang, J. M.

AU - Huang, X.

AU - Han, D.

AU - Huang, S.

AU - Zhao, Y.

AU - Zha, R.

AU - He, X.

AU - Wu, X.

PY - 2013/6/20

Y1 - 2013/6/20

N2 - The purpose of this study was to define the roles of miR-181a in determining sensitivity of cervical cancer to radiation therapy, to explore the underlying mechanism and to evaluate the potential of miR-181a as a biomarker for predicting radio-sensitivity. Tumor specimens from 18 patients with a histological diagnosis of squamous cervical carcinoma (stage IIIB) were used in the micro-RNA profiling and comparison. These patients never received any chemotherapy before radiation therapy. Human cervical cancer cell lines, SiHa and Me180, were used in vitro (cell culture) and in vivo (animal) studies. Transfection of tumor cells with the mimic or inhibitor of miR-181a, and reporter gene assay, were performed to investigate the role of miR-181a in determining radio-sensitivity and the target gene. Higher expression of miR-181a was observed in human cervical cancer specimens and cell lines that were insensitive to radiation therapy, as compared with sensitive cancer specimens and the cell lines. We also found that miR-181a negatively regulated the expression of PRKCD, a pro-apoptotic protein kinase, via targeting its 3′-untranslated region (UTR), thereby inhibiting irradiation-induced apoptosis and decreasing G 2/M block. The role of miR-181a in conferring cellular resistance to radiation treatment was validated both in cell culture models and in mouse tumor xenograft models. The effect of miR-181a on radio-resistance was mediated through targeting the 3′-UTR of PRKCD gene. Thus, the expression level of miR-181a in cervical cancer may serve as a biomarker for sensitivity to radiation therapy, and targeting miR-181a may represent a new approach to sensitizing cervical cancer to radiation treatment.

AB - The purpose of this study was to define the roles of miR-181a in determining sensitivity of cervical cancer to radiation therapy, to explore the underlying mechanism and to evaluate the potential of miR-181a as a biomarker for predicting radio-sensitivity. Tumor specimens from 18 patients with a histological diagnosis of squamous cervical carcinoma (stage IIIB) were used in the micro-RNA profiling and comparison. These patients never received any chemotherapy before radiation therapy. Human cervical cancer cell lines, SiHa and Me180, were used in vitro (cell culture) and in vivo (animal) studies. Transfection of tumor cells with the mimic or inhibitor of miR-181a, and reporter gene assay, were performed to investigate the role of miR-181a in determining radio-sensitivity and the target gene. Higher expression of miR-181a was observed in human cervical cancer specimens and cell lines that were insensitive to radiation therapy, as compared with sensitive cancer specimens and the cell lines. We also found that miR-181a negatively regulated the expression of PRKCD, a pro-apoptotic protein kinase, via targeting its 3′-untranslated region (UTR), thereby inhibiting irradiation-induced apoptosis and decreasing G 2/M block. The role of miR-181a in conferring cellular resistance to radiation treatment was validated both in cell culture models and in mouse tumor xenograft models. The effect of miR-181a on radio-resistance was mediated through targeting the 3′-UTR of PRKCD gene. Thus, the expression level of miR-181a in cervical cancer may serve as a biomarker for sensitivity to radiation therapy, and targeting miR-181a may represent a new approach to sensitizing cervical cancer to radiation treatment.

UR - http://www.scopus.com/inward/record.url?scp=84879414000&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879414000&partnerID=8YFLogxK

U2 - 10.1038/onc.2012.323

DO - 10.1038/onc.2012.323

M3 - Article

C2 - 22847611

AN - SCOPUS:84879414000

VL - 32

SP - 3019

EP - 3027

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 25

ER -